XENE Long Put Strategy
XENE (Xenon Pharmaceuticals Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development.
XENE (Xenon Pharmaceuticals Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $6.31B, a beta of 0.63 versus the broader market, a 52-week range of 35.6-72.66, average daily share volume of 1.2M, a public-listing history dating back to 2014, approximately 364 full-time employees. These structural characteristics shape how XENE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.63 indicates XENE has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a long put on XENE?
A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration.
XENE snapshot
As of August 14, 2026, spot at $62.17, ATM IV 46.60%, IV rank 6.64%, expected move 13.36%. The long put on XENE below is built from the August 14, 2026 end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 7-day expiry.
Why this long put structure on XENE specifically: XENE IV at 46.60% is on the cheap side of its 1-year range, which favors premium-buying structures like a XENE long put, with a market-implied 1-standard-deviation move of approximately 13.36% (roughly $8.31 on the underlying). The 7-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated XENE expiries trade a higher absolute premium for lower per-day decay. Position sizing on XENE should anchor to the underlying notional of $62.17 per share and to the trader's directional view on XENE stock.
XENE long put setup
The XENE long put below is built from the August 14, 2026 end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With XENE at $62.17 on that close, the first option leg uses a $62.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed XENE chain at a 7-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 XENE shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $62.50 | $1.38 |
XENE long put risk and reward
- Net Premium / Debit
- -$137.50
- Max Profit (per contract)
- $6,111.50
- Max Loss (per contract)
- -$137.50
- Breakeven(s)
- $61.13
- Risk / Reward Ratio
- 44.447
Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium.
XENE long put payoff curve
Modeled P&L at expiration across a range of underlying prices for the long put on XENE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | +$6,111.50 |
| $13.76 | -77.9% | +$4,737.00 |
| $27.50 | -55.8% | +$3,362.49 |
| $41.25 | -33.7% | +$1,987.99 |
| $54.99 | -11.5% | +$613.49 |
| $68.74 | +10.6% | -$137.50 |
| $82.48 | +32.7% | -$137.50 |
| $96.23 | +54.8% | -$137.50 |
| $109.97 | +76.9% | -$137.50 |
| $123.72 | +99.0% | -$137.50 |
When traders use long put on XENE
Long puts on XENE hedge an existing long XENE stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying XENE exposure being hedged.
XENE thesis for this long put
The market-implied 1-standard-deviation range for XENE extends from approximately $53.86 on the downside to $70.48 on the upside. A XENE long put expresses a directional view that the underlying closes below the strike minus premium at expiration, frequently sized to hedge an existing long XENE position with one put per 100 shares held. Current XENE IV rank near 6.64% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on XENE at 46.60%. As a Healthcare name, XENE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to XENE-specific events.
XENE long put positions are structurally bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. XENE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move XENE alongside the broader basket even when XENE-specific fundamentals are unchanged. Long-premium structures like a long put on XENE are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current XENE chain quotes before placing a trade.
Frequently asked questions
- What is a long put on XENE?
- A long put on XENE is the long put strategy applied to XENE (stock). The strategy is structurally bearish: A long put buys downside exposure with a fixed maximum loss equal to the premium paid; profit accrues if the underlying closes below the strike minus premium at expiration. With XENE stock at $62.17 on the August 14, 2026 close, the strikes shown on this page are snapped to the nearest listed XENE chain strike and the premiums come straight from that session's bid/ask midpoint.
- How are XENE long put max profit and max loss calculated?
- Max profit equals the strike minus premium times 100 (reached at zero); max loss equals the premium times 100. Breakeven is strike minus premium. For the XENE long put priced from the August 14, 2026 end-of-day chain at a 30-day expiry (ATM IV 46.60%), the computed maximum profit is $6,111.50 per contract and the computed maximum loss is -$137.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a XENE long put?
- The breakeven for the XENE long put priced on this page is roughly $61.13 at expiration, derived from the August 14, 2026 end-of-day chain's premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The XENE market-implied 1-standard-deviation expected move in the same options snapshot is approximately 13.36%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a long put on XENE?
- Long puts on XENE hedge an existing long XENE stock position or express a bearish view with defined risk; position sizing typically scales the put notional to the underlying XENE exposure being hedged.
- How does current XENE implied volatility affect this long put?
- XENE ATM IV is at 46.60% with IV rank near 6.64%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.